MO-0058 Cost-effectiveness of hypofractionated radiotherapy in intermediate-risk prostate cancer. (May 2022) - Renouf, M.; Zhou, K.; Perrocheau, G.; Magné, N.; De Brisson de la Roche, G.; Latorzeff, I.; Pommier, P.; Créhange, G.; Paumier, A.; Bera, G.; Catton, C.; Bellanger, M.; et al.